arXiv Preprint Archive
March 12, 2026
Yuxin Zhu, Sahithi Lakamana, Masoud Rouhizadeh et al.
preprint
Treatment-resistant depression (TRD) is a severe form of major depressive disorder in which patients do not achieve remission despite multiple adequate treatment trials. Evidence across pharmacologic options for TRD remains limited, and trials often do not fully capture patient-reported tolerability. Large-scale online peer-support narratives therefore offer a complementary lens on how patients...
Editora Pasteur eBooks
March 11, 2026
Ana Carolina Baldi Pasqualini, Henrique Wojciechowski Osorio, Veridiana Powarczuk et al.
Introdução: Os transtornos psiquiátricos representam um importante desafio na saúde pública mundial, com impacto significativo na qualidade de vida, funcionalidade e mortalidade dos pacientes. Embora os psicofármacos tradicionais, como antidepressivos, antipsicóticos e estabilizadores de humor sejam amplamente utilizados, muitos indivíduos apresentam resposta insatisfatória, falha terapêutica...
CNS Spectrums
March 10, 2026
Halima Faisal, Gia Han Le, Angela T H Kwan et al.
Background: Anhedonia and reward-processing deficits are core features of major depressive disorder (MDD) that respond poorly to traditional antidepressants.Ketamine has rapid antidepressant effects, yet its neurofunctional actions within reward circuits remain unclear.We synthesized human neuroimaging evidence on ketamine-related modulation of reward circuitry and implications for...
Frontiers in Psychiatry
March 4, 2026
Robert Queissner, F. Fellendorf, E. Z. Reininghaus
Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharmacotherapies often provide delayed or incomplete relief and may increase the risk of treatment-emergent affective switching. Recent evidence highlights the therapeutic potential of NMDA receptor antagonists, particularly ketamine and its S-enantiomer...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
February 27, 2026
Chris H. Miller, Angela Hickman, Caitlin Baten et al.
2 citations
Ketamine pharmacotherapy provides a novel treatment option for major depressive disorder (MDD) and has generated a large, growing body of research regarding its biochemical and clinical properties. This narrative review summarizes the history of ketamine's development, beginning as a general anesthetic, continuing with a discovery of its antidepressant properties, and leading up to its landmark...
AJN, American Journal of Nursing
February 19, 2026
Liz Braun, Alison Colbert
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic stress disorder. With rising global mental health burdens and the limitations of existing pharmacological treatments, ketamine's novel mechanism of action provides a potential alternative for individuals who have not responded to traditional therapies....
February 10, 2026
Jolien K E Veraart
This thesis explores the use of ketamine in people with treatment-resistant depression. It starts by examining the concept of treatment-resistant depression, a term that is widely used but poorly defined. Importantly, this label may negatively influence patients’ expectations and sense of hope. As an alternative, more neutral framing is suggested.Survey data from individuals seeking ketamine...
The Journal of Sexual Medicine
February 1, 2026
Hendrikus Knegtering, Thalia Herder, Nynke Boonstra et al.
Psychedelic-assisted therapy (PAT) is increasingly investigated as a treatment for depression, post-traumatic stress disorder (PTSD), and substance use disorder. In the United States (US) and European Union, esketamine has been approved for the treatment of depression, while psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) have received Breakthrough Therapy Designation in the US for...
Mental Health Clinician
February 1, 2026
Parna Haghparast, Busuyi Olotu, Carol Yuan
MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents,...
Pediatric research
January 27, 2026
Saihao Fu, Mengrong Miao, Jing Bian et al.
1 citation
To explore the efficacy of perioperative medications in preventing emergence agitation (EA) in children after sevoflurane anaesthesia. This network meta-analysis used a frequency-analysis model. PubMed, Embase, Cochrane Library, Web of Science, Google Scholar and ClinicalTrials.gov databases were searched from inception to March 11, 2023. A total of 19 drugs were analysed in 70 studies...